Have a feature idea you'd love to see implemented?
Let us know!
ACRS Aclaris Therapeutics Inc
Price (delayed)
$4.32
Market cap
$308.58M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.52
Enterprise value
$260.93M
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The
Highlights
ACRS's debt has plunged by 100% YoY
ACRS's gross profit has soared by 75% YoY and by 6% from the previous quarter
Aclaris Therapeutics's quick ratio has surged by 80% YoY but it has decreased by 4.1% QoQ
The company's revenue rose by 26% YoY but it fell by 15% QoQ
ACRS's equity is down by 17% YoY and by 2.7% QoQ
Key stats
What are the main financial stats of ACRS
Market
Valuations
Earnings
Shares outstanding
71.43M
Market cap
$308.58M
Enterprise value
$260.93M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.37
Price to sales (P/S)
11.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.64
Revenue
$27.08M
EBIT
-$37.37M
EBITDA
-$36.48M
Free cash flow
-$18.46M
Per share
Balance sheet
Liquidity
EPS
-$0.52
Free cash flow per share
-$0.26
Book value per share
$1.82
Revenue per share
$0.38
TBVPS
$2.56
Total assets
$182.39M
Total liabilities
$52.24M
Debt
$0
Equity
$130.15M
Working capital
$113.51M
Debt to equity
0
Current ratio
7.03
Quick ratio
6.81
Net debt/EBITDA
1.31
Margins
Efficiency
Dividend
EBITDA margin
-134.7%
Gross margin
53.5%
Net margin
-136.6%
Operating margin
-254.1%
Return on assets
-20.7%
Return on equity
-26.3%
Return on invested capital
-30.9%
Return on capital employed
-22.8%
Return on sales
-138%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACRS stock price
How has the Aclaris Therapeutics stock price performed over time
Intraday
9.09%
1 week
98.17%
1 month
257.02%
1 year
385.34%
YTD
311.43%
QTD
275.65%
Financial performance
How have Aclaris Therapeutics's revenue and profit performed over time
Revenue
$27.08M
Gross profit
$14.5M
Operating income
-$68.8M
Net income
-$37M
Gross margin
53.5%
Net margin
-136.6%
ACRS's gross profit has soared by 75% YoY and by 6% from the previous quarter
ACRS's net margin has soared by 74% YoY and by 25% from the previous quarter
The company's net income has surged by 68% YoY and by 37% QoQ
Aclaris Therapeutics's operating margin has soared by 53% YoY and by 9% from the previous quarter
Growth
What is Aclaris Therapeutics's growth rate over time
Valuation
What is Aclaris Therapeutics stock price valuation
P/E
N/A
P/B
2.37
P/S
11.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.64
Aclaris Therapeutics's EPS has surged by 69% YoY and by 37% QoQ
ACRS's P/B is 38% below its 5-year quarterly average of 3.5
ACRS's equity is down by 17% YoY and by 2.7% QoQ
ACRS's P/S is 82% below its 5-year quarterly average of 59.0
The company's revenue rose by 26% YoY but it fell by 15% QoQ
Efficiency
How efficient is Aclaris Therapeutics business performance
Aclaris Therapeutics's return on sales has surged by 74% YoY and by 25% QoQ
The company's return on equity has surged by 59% YoY and by 34% QoQ
The ROA has soared by 58% YoY and by 34% from the previous quarter
Aclaris Therapeutics's return on invested capital has surged by 55% YoY and by 33% QoQ
Dividends
What is ACRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACRS.
Financial health
How did Aclaris Therapeutics financials performed over time
Aclaris Therapeutics's total liabilities has soared by 92% from the previous quarter but it has decreased by 16% YoY
Aclaris Therapeutics's quick ratio has surged by 80% YoY but it has decreased by 4.1% QoQ
ACRS's debt is 100% less than its equity
ACRS's debt has plunged by 100% YoY
ACRS's equity is down by 17% YoY and by 2.7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.